Although we have focussed upon increased expression of MHC-I as a mechanism of increased tumor immunogenicity in this study, our findings of increased expression of other tumor ligands such as Fas, TRAIL, and NKG2DL (RAE-1) in vitro suggests that further investigation into the relevance of these pathways in the observed therapeutic effects of MEKi is warranted. Here, RAE1 is linked to neoplasm.